Connection

NABIL AHMED to Humans

This is a "connection" page, showing publications NABIL AHMED has written about Humans.
Connection Strength

0.352
  1. Autologous HER2-specific CAR T cells after lymphodepletion for advanced sarcoma: a phase 1 trial. Nat Cancer. 2024 Jun; 5(6):880-894.
    View in: PubMed
    Score: 0.018
  2. Tumor response and endogenous immune reactivity after administration of HER2 CAR T cells in a child with metastatic rhabdomyosarcoma. Nat Commun. 2020 07 15; 11(1):3549.
    View in: PubMed
    Score: 0.014
  3. Effect of sample type and storage conditions on Golgi membrane protein 73 stability. Scand J Clin Lab Invest. 2019 Nov; 79(7):491-495.
    View in: PubMed
    Score: 0.013
  4. Response to the comment on "Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma" by Bielamowicz et al. Neuro Oncol. 2018 06 18; 20(7):1004-1005.
    View in: PubMed
    Score: 0.012
  5. Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma. Neuro Oncol. 2018 03 27; 20(4):506-518.
    View in: PubMed
    Score: 0.012
  6. HER2-Specific Chimeric Antigen Receptor-Modified Virus-Specific T Cells for Progressive Glioblastoma: A Phase 1 Dose-Escalation Trial. JAMA Oncol. 2017 Aug 01; 3(8):1094-1101.
    View in: PubMed
    Score: 0.011
  7. Realism and pragmatism in developing an effective chimeric antigen receptor T-cell product for solid cancers. Cytotherapy. 2016 11; 18(11):1382-1392.
    View in: PubMed
    Score: 0.011
  8. Tandem CAR T cells targeting HER2 and IL13Ra2 mitigate tumor antigen escape. J Clin Invest. 2016 08 01; 126(8):3036-52.
    View in: PubMed
    Score: 0.011
  9. Targeting the tumour profile using broad spectrum chimaeric antigen receptor T-cells. Biochem Soc Trans. 2016 Apr 15; 44(2):391-6.
    View in: PubMed
    Score: 0.010
  10. Is CMV a target in pediatric glioblastoma? Expression of CMV proteins, pp65 and IE1-72 and CMV nucleic acids in a cohort of pediatric glioblastoma patients. J Neurooncol. 2015 Nov; 125(2):307-15.
    View in: PubMed
    Score: 0.010
  11. The Evolution of T-cell Therapies for Solid Malignancies. Clin Cancer Res. 2015 Aug 01; 21(15):3384-92.
    View in: PubMed
    Score: 0.010
  12. Polystyrene microspheres enable 10-color compensation for immunophenotyping of primary human leukocytes. Cytometry A. 2015 Nov; 87(11):1038-46.
    View in: PubMed
    Score: 0.010
  13. Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma. J Clin Oncol. 2015 May 20; 33(15):1688-96.
    View in: PubMed
    Score: 0.010
  14. Armed hunter killers: discerning the role of adoptive T-cell transfer for glioblastoma. Immunotherapy. 2015; 7(5):481-5.
    View in: PubMed
    Score: 0.010
  15. Cellular immunotherapy for pediatric solid tumors. Cytotherapy. 2015 Jan; 17(1):3-17.
    View in: PubMed
    Score: 0.009
  16. Novel approaches and mechanisms of immunotherapy for glioblastoma. Discov Med. 2014 Mar; 17(93):145-54.
    View in: PubMed
    Score: 0.009
  17. Combinational targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in glioblastoma. Mol Ther. 2013 Nov; 21(11):2087-101.
    View in: PubMed
    Score: 0.009
  18. Medulloblastoma-biology and microenvironment: a review. Pediatr Hematol Oncol. 2012 Sep; 29(6):495-506.
    View in: PubMed
    Score: 0.008
  19. Generation of polyclonal CMV-specific T cells for the adoptive immunotherapy of glioblastoma. J Immunother. 2012 Feb-Mar; 35(2):159-68.
    View in: PubMed
    Score: 0.008
  20. Crosstalk between medulloblastoma cells and endothelium triggers a strong chemotactic signal recruiting T lymphocytes to the tumor microenvironment. PLoS One. 2011; 6(5):e20267.
    View in: PubMed
    Score: 0.007
  21. T-cell-based therapies for malignancy and infection in childhood. Pediatr Clin North Am. 2010 Feb; 57(1):83-96.
    View in: PubMed
    Score: 0.007
  22. HER2-specific T cells target primary glioblastoma stem cells and induce regression of autologous experimental tumors. Clin Cancer Res. 2010 Jan 15; 16(2):474-85.
    View in: PubMed
    Score: 0.007
  23. Immunotherapy for osteosarcoma: genetic modification of T cells overcomes low levels of tumor antigen expression. Mol Ther. 2009 Oct; 17(10):1779-87.
    View in: PubMed
    Score: 0.007
  24. How to design effective vaccines: lessons from an old success story. Expert Rev Vaccines. 2009 May; 8(5):543-6.
    View in: PubMed
    Score: 0.006
  25. Successful treatment of stem cell graft failure in pediatric patients using a submyeloablative regimen of campath-1H and fludarabine. Biol Blood Marrow Transplant. 2008 Nov; 14(11):1298-304.
    View in: PubMed
    Score: 0.006
  26. Acute hepatic sequestration associated with pneumococcal infection in a 5-year-old Boy with sickle beta degrees -thalassemia: a case report and review of the literature. J Pediatr Hematol Oncol. 2007 Oct; 29(10):720-4.
    View in: PubMed
    Score: 0.006
  27. Regression of experimental medulloblastoma following transfer of HER2-specific T cells. Cancer Res. 2007 Jun 15; 67(12):5957-64.
    View in: PubMed
    Score: 0.006
  28. Viral lymphomagenesis. Curr Opin Hematol. 2006 Jul; 13(4):254-9.
    View in: PubMed
    Score: 0.005
  29. Identification of a clinically efficacious CAR T cell subset in diffuse large B cell lymphoma by dynamic multidimensional single-cell profiling. Nat Cancer. 2024 Jul; 5(7):1010-1023.
    View in: PubMed
    Score: 0.005
  30. Prolonged cytopenias after immune effector cell therapy and lymphodepletion in patients with leukemia, lymphoma and solid tumors. Cytotherapy. 2024 Sep; 26(9):1026-1032.
    View in: PubMed
    Score: 0.005
  31. Targeting GBM with an Oncolytic Picornavirus SVV-001 alone and in combination with fractionated Radiation in a Novel Panel of Orthotopic PDX models. J Transl Med. 2023 07 06; 21(1):444.
    View in: PubMed
    Score: 0.004
  32. Cord blood transplantation for nonmalignant disorders: early functional immunity and high survival. Blood Adv. 2023 05 09; 7(9):1823-1830.
    View in: PubMed
    Score: 0.004
  33. Long-term follow-up for the development of subsequent malignancies in patients treated with genetically modified IECs. Blood. 2022 07 07; 140(1):16-24.
    View in: PubMed
    Score: 0.004
  34. Ghrelin polymorphism/TRPV1 receptor expression in Egyptian IBS patients. Cytokine. 2022 04; 152:155827.
    View in: PubMed
    Score: 0.004
  35. Immunogenicity of CAR T cells in cancer therapy. Nat Rev Clin Oncol. 2021 06; 18(6):379-393.
    View in: PubMed
    Score: 0.004
  36. Locoregional delivery of CAR T cells to the cerebrospinal fluid for treatment of metastatic medulloblastoma and ependymoma. Nat Med. 2020 05; 26(5):720-731.
    View in: PubMed
    Score: 0.003
  37. CAR T-cells that target acute B-lineage leukemia irrespective of CD19 expression. Leukemia. 2021 01; 35(1):75-89.
    View in: PubMed
    Score: 0.003
  38. Immunotherapy for pediatric brain tumors: past and present. Neuro Oncol. 2019 10 09; 21(10):1226-1238.
    View in: PubMed
    Score: 0.003
  39. CNS Langerhans cell histiocytosis: Common hematopoietic origin for LCH-associated neurodegeneration and mass lesions. Cancer. 2018 06 15; 124(12):2607-2620.
    View in: PubMed
    Score: 0.003
  40. High Incidence of Autoimmune Disease after Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease. Biol Blood Marrow Transplant. 2018 08; 24(8):1643-1650.
    View in: PubMed
    Score: 0.003
  41. Current Allogeneic Hematopoietic Stem Cell Transplantation for Pediatric Acute Lymphocytic Leukemia: Success, Failure and Future Perspectives-A Single-Center Experience, 2008 to 2016. Biol Blood Marrow Transplant. 2018 07; 24(7):1424-1431.
    View in: PubMed
    Score: 0.003
  42. TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer. Cancer Res. 2018 01 15; 78(2):489-500.
    View in: PubMed
    Score: 0.003
  43. Outcomes after Allogeneic Transplant in Patients with Wiskott-Aldrich Syndrome. Biol Blood Marrow Transplant. 2018 03; 24(3):537-541.
    View in: PubMed
    Score: 0.003
  44. LC3A Silencing Hinders Aggresome Vimentin Cage Clearance in Primary Choroid Plexus Carcinoma. Sci Rep. 2017 08 14; 7(1):8022.
    View in: PubMed
    Score: 0.003
  45. Quantitative Imaging Approaches to Study the CAR Immunological Synapse. Mol Ther. 2017 08 02; 25(8):1757-1768.
    View in: PubMed
    Score: 0.003
  46. Identification of diverse astrocyte populations and their malignant analogs. Nat Neurosci. 2017 Mar; 20(3):396-405.
    View in: PubMed
    Score: 0.003
  47. Gene therapy: charting a future course--summary of a National Institutes of Health Workshop, April 12, 2013. Hum Gene Ther. 2014 Jun; 25(6):488-97.
    View in: PubMed
    Score: 0.002
  48. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10; 124(2):188-95.
    View in: PubMed
    Score: 0.002
  49. T cells redirected to interleukin-13Ra2 with interleukin-13 mutein--chimeric antigen receptors have anti-glioma activity but also recognize interleukin-13Ra1. Cytotherapy. 2014 Aug; 16(8):1121-31.
    View in: PubMed
    Score: 0.002
  50. Overexpression and constitutive nuclear localization of cohesin protease Separase protein correlates with high incidence of relapse and reduced overall survival in glioblastoma multiforme. J Neurooncol. 2014 Aug; 119(1):27-35.
    View in: PubMed
    Score: 0.002
  51. The miR-223/nuclear factor I-A axis regulates glial precursor proliferation and tumorigenesis in the CNS. J Neurosci. 2013 Aug 14; 33(33):13560-8.
    View in: PubMed
    Score: 0.002
  52. Medulloblastoma expresses CD1d and can be targeted for immunotherapy with NKT cells. Clin Immunol. 2013 Oct; 149(1):55-64.
    View in: PubMed
    Score: 0.002
  53. T cells redirected to EphA2 for the immunotherapy of glioblastoma. Mol Ther. 2013 Mar; 21(3):629-37.
    View in: PubMed
    Score: 0.002
  54. PiggyBac-mediated cancer immunotherapy using EBV-specific cytotoxic T-cells expressing HER2-specific chimeric antigen receptor. Mol Ther. 2011 Dec; 19(12):2133-43.
    View in: PubMed
    Score: 0.002
  55. Nanoshell-mediated photothermal therapy improves survival in a murine glioma model. J Neurooncol. 2011 Aug; 104(1):55-63.
    View in: PubMed
    Score: 0.002
  56. Glioma cells display complex cell surface topographies that resist the actions of cytolytic effector lymphocytes. J Immunol. 2010 Oct 15; 185(8):4793-803.
    View in: PubMed
    Score: 0.002
  57. A simple and sensitive method for measuring tumor-specific T cell cytotoxicity. PLoS One. 2010 Jul 29; 5(7):e11867.
    View in: PubMed
    Score: 0.002
  58. Immunotherapy for pediatric central nervous system tumors. Biol Blood Marrow Transplant. 2010 Jan; 16(1 Suppl):S75-81.
    View in: PubMed
    Score: 0.002
  59. Contact-activated monocytes: efficient antigen presenting cells for the stimulation of antigen-specific T cells. J Immunother. 2007 Jan; 30(1):96-107.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.